-
公开(公告)号：EP1304121A4
公开(公告)日：2004-06-23
申请号：EP00974859
申请日：2000-11-09
发明人： SUGIYAMA YASUO , ODAKA HIROYUKI , KIMURA HIROYUKI
IPC分类号： A61K31/00 , A61K31/195 , A61K31/235 , A61K31/421 , A61K45/06 , A61P3/04 , A61P3/10 , C07D263/32 , A61K45/00
CPC分类号： C07D263/32 , A61K31/00 , A61K31/195 , A61K31/235 , A61K31/421 , A61K45/06 , A61K2300/00
摘要： Body weight gain inhibitors comprises PPARη agonist-like substances, which contain PPARδ agonist-like substances such as compounds represented by general formula (I) wherein R1 represents optionally substituted hydrocarbyl, etc.; X represents a bond, etc.; Y represents oxygen, etc.; the ring A represents a heterocycle, etc.; R2 represents hydrogen, etc.; R3 represents-OR9, etc.; and R4 and R5 represent each hydrogen, etc., are useful in treating diabetes, etc.
摘要翻译： 体重增加抑制剂包含PPARδ激动剂样物质，其含有PPARδ激动剂样物质，例如通式（I）所代表的化合物，其中R 1代表任选取代的烃基等; X代表债券等; Y代表氧气等; 环A表示杂环等; R2代表氢等; R3代表-OR9等; R4和R5各自代表氢等，可用于治疗糖尿病等。
-
公开(公告)号：EP1275388A4
公开(公告)日：2003-11-26
申请号：EP01904345
申请日：2001-02-08
发明人： SUGIYAMA YASUO , ODAKA HIROYUKI , NARUO KEN-ICHI , FUNATSU MASAMI , IKEYA KAZUAKI , SUZUKI YOSHIHARU
IPC分类号： A61K31/22 , A61K31/366 , A61K31/40 , A61K31/4418 , A61K31/4709 , A61K31/505 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/10 , A61P13/12 , A61P19/02 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/12 , A61P37/02 , A61P43/00 , A61K31/405 , A61K31/4409
CPC分类号： A61K31/505 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/4418 , A61K31/4709
摘要： TNF- inhibitors containing at least one compound selected from among serivastatin, atorvastatin, simvastatin, pravastatin, itavastatin and (+)-(3R,5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino)pyrimidin-5-yl]-3,5-dihydroxy-6(E)-heptenoic acid and salts thereof which have sufficiently favorable properties as drugs, for example, exhibiting excellent preventive and therapeutic effects on TNF-α-associated diseases such as inflammatory diseases without showing any side effects.
-
公开(公告)号：EP1254667A4
公开(公告)日：2003-03-12
申请号：EP01904344
申请日：2001-02-08
发明人： SUGIYAMA YASUO , ODAKA HIROYUKI , NARUO KEN-ICHI
IPC分类号： A61K31/22 , A61K31/366 , A61K31/40 , A61K31/427 , A61K31/44 , A61K31/4439 , A61K45/06 , A61P1/04 , A61P19/02 , A61P29/00 , C07D263/44 , C07D413/12 , C07D413/14 , C07D417/06 , A61K31/42 , A61K31/425 , C07D277/34 , C07D413/06 , C07D417/12
CPC分类号： C07D263/44 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/427 , A61K31/44 , A61K31/4439 , A61K45/06 , C07D413/12 , C07D413/14 , C07D417/06 , A61K2300/00
摘要： A TNF-α inhibitor comprising a combination of an insulin resistance-ameliorating agent with an HMG-CoA reductase inhibitor which is useful as a preventive or a remedy for inflammatory diseases, etc.
-
公开(公告)号：EP1092711A4
公开(公告)日：2002-07-31
申请号：EP99926853
申请日：1999-06-30
发明人： SUGIYAMA YASUO , MOMOSE YU , KIMURA HIROYUKI , SAKAMOTO JUNICHI , ODAKA HIROYUKI
IPC分类号： C07D233/54 , C07D263/32 , C07D277/30 , C07D413/04 , C07D417/04 , C07D263/30 , A61K31/42 , A61K31/425 , A61K31/44
CPC分类号： C07D413/04 , C07D263/32 , C07D277/30 , C07D417/04
摘要： Retinoid-associated receptor regulators containing 1,3-azole derivatives represented by general formula (I) or salts thereof wherein R1 represents optionally substituted aromatic hydrocarbyl or heteroaryl; R2 represents hydrogen or optionally substituted hydrocarbyl; X represents O, s or -NR4-; A represents optionally substituted aromatic hydrocarbyl or heteroaryl; and R3 represents -OR?5 or -NR6R7¿. These products are usable as, for example, preventives and remedies for diabetes, etc.
-
公开(公告)号：EP1295609A4
公开(公告)日：2004-11-03
申请号：EP01906193
申请日：2001-02-22
IPC分类号： A61K31/00 , A61K45/06 , A61P3/10 , A61P43/00 , A61K31/133 , A61K31/198 , A61K31/405 , A61K31/44 , A61K31/451 , A61K31/70 , A61K31/7008 , A61K31/702
摘要： Drugs containing, as the active ingredients, exclusively a combination of an α-glucosidase inhibitor with a non-sulfonylurea insulin secretion promoter which are useful as preventives and remedies for diabetes, etc.
-
公开(公告)号：EP1357115A4
公开(公告)日：2004-04-07
申请号：EP01272544
申请日：2001-12-28
发明人： MOMOSE YU , MAEKAWA TSUYOSHI , TAKAKURA NOBUYUKI , ODAKA HIROYUKI , KIMURA HIROYUKI , ITO TATSUYA
IPC分类号： A61P3/06 , A61P3/10 , A61P9/12 , A61P13/12 , A61P19/10 , A61P27/02 , A61P31/04 , A61P43/00 , C07D263/32 , C07D277/24 , C07D277/32 , C07D277/34 , C07D277/42 , C07D403/04 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
CPC分类号： C07D403/04 , C07D263/32 , C07D277/24 , C07D277/42 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
摘要： Alkanoic acid derivatives represented by the general formula (I) or salts thereof, useful as preventive and/or therapeutic agents for diabetes, hyperlipidemia, impaired glucose tolerance, and so on: (I) wherein R1 is an optionally substituted five-membered aromatic heterocyclic group; X is a free valency or the like; Q is a divalent hydrocarbon group containing 1 to 20 carbon atoms; Y is a free valency or the like; A is an aromatic ring which may have one to three substituents; Z is -(CH¿2)n-Z?1- (wherein n is an integer of 1 to 8; and Z1 is oxygen or the like) or the like; B is an optionally mono- to tri-substituted pyridine ring or the like; U is a free valency or the like; W is a divalent hydrocarbon group containing 1 to 20 carbon atoms; and R3 is -OH or the like, with the proviso that when B is an optionally mono- to tri-substituted benzene ring, U is a free valency.
-
公开(公告)号：EP1229026A4
公开(公告)日：2003-09-24
申请号：EP00974858
申请日：2000-11-09
发明人： MOMOSE YU , IMOTO HIROSHI , ODAKA HIROYUKI , KIMURA HIROYUKI
IPC分类号： A61K31/421 , A61K31/4439 , A61P3/06 , A61P3/10 , C07C251/54 , C07D213/89 , C07D263/32 , A61K31/195 , A61K31/235 , A61K31/42 , C07D413/12
CPC分类号： C07D213/89 , A61K31/421 , A61K31/4439 , C07C251/54 , Y02P20/55
摘要： Compounds of general formula (I) or salts thereof are useful as preventive or therapeutic agents for diabetes and so on wherein R1 is an optionally substituted hydrocarbon group or the like; X is a free valency or the like; Y is oxygen or the like; A is a heterocycle or the like; R2 is hydrogen or the like; R?3 is OR9¿ or the like; and R?4 and R5¿ are each hydrogen or the like, with the provisos that when A is optionally substituted indole, Y is not oxygen or sulfur, that when Y is oxygen, sulfur, -SO-, -SO¿2?-, or -NR?8¿-, A is not an optionally substituted benzene ring, and that when Y is oxygen and A is an optionally substituted, 4-pyrone, 4-pyridone, or pyridine N-oxide ring, R2 is not a thiazolyl or thiadiazolyl group substituted with optionally protected amino.
摘要翻译： 通式（I）的化合物或其盐可用作糖尿病等的预防或治疗剂，其中R 1是任选取代的烃基等; X是自由价或类似物; Y是氧或类似物; A是杂环等; R2是氢等; R 3是OR 9或类似的; 并且R 4和R 5各自为氢等，条件是当A是任选取代的吲哚时，Y不是氧或硫，当Y是氧时，硫，-SO - ， - SO 2 - ，或-NR8-，A不是任选取代的苯环，并且当Y是氧且A是任选取代的4-吡喃酮，4-吡啶酮或吡啶N-氧化物环时，R2不是 噻唑基或噻二唑基，其被任选保护的氨基取代。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.009 秒)
